Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (IMAGO)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Lumena Pharmaceuticals, Inc.
Sponsor:
Information provided by (Responsible Party):
Lumena Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01903460
First received: July 16, 2013
Last updated: September 16, 2014
Last verified: September 2013
  Purpose

The study is a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LUM001. Efficacy will be assessed by evaluating the effect of LUM001 versus placebo on the biochemical markers and pruritus associated with Alagille Syndrome.


Condition Intervention Phase
Alagille Syndrome
Drug: LUM001
Drug: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of LUM001, an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTi), in the Treatment of Cholestatic Liver Disease in Paediatric Patients With Alagille Syndrome

Resource links provided by NLM:


Further study details as provided by Lumena Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Efficacy [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
    Change from baseline in fasting serum bile acids compared to placebo


Secondary Outcome Measures:
  • Efficacy [ Time Frame: 13 weeks ] [ Designated as safety issue: No ]
    Change from baseline in liver enzymes and pruritus compared to placebo


Other Outcome Measures:
  • Safety and Tolerability [ Time Frame: 13 weeks ] [ Designated as safety issue: Yes ]
    Evaluation of adverse events, changes in vital signs, laboratory and other safety parameters


Estimated Enrollment: 18
Study Start Date: August 2013
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: September 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LUM001
LUM001 administered orally once each day
Drug: LUM001
Placebo Comparator: Placebo
Placebo administered orally once each day
Drug: Placebo

  Eligibility

Ages Eligible for Study:   12 Months to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of Alagille Syndrome
  2. Evidence of cholestasis
  3. Moderate to severe pruritus
  4. Ability to understand and willingness to sign informed consent/assent prior to initiation of any study procedures

Exclusion Criteria:

  1. Surgical disruption of the enterohepatic circulation
  2. Liver transplant
  3. History or presence of other concomitant liver disease
  4. Females who are pregnant or lactating
  5. Known HIV infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01903460

Contacts
Contact: Sara Barbat, BSN, RN 858-461-0694 info@lumenapharma.com

Locations
United Kingdom
Birmingham Children's Hospital Recruiting
Birmingham, West Midlands, United Kingdom, B4 6NH
Contact: Carla Lloyd       carla.lloyd@bch.nhs.uk   
Contact: Gemma Slinn       Gemma.slinn@bch.nhs.uk   
Principal Investigator: Deirdre Kelly, FRCPI, FRCP,FRCPCH         
Leeds Teaching Hospitals Recruiting
Leeds, West Yorkshire, United Kingdom, LS9 7TF
Contact: Sarah Ashton       sarah.ashton@cmft.nhs.uk   
Contact: Nicola Balatoni       nicola.balatoni@leedsth.nhs.uk   
Principal Investigator: Patricia McClean, MD,FRCP,FRCPCH         
Kings College Hospital Recruiting
London, United Kingdom, SE5 9RS
Contact: Palaniswamy Karthikeyan       pkarthikeyan@nhs.net   
Contact: Harpreet Grewal       harpreet.grewal@kcl.ac.uk   
Principal Investigator: Alastair Baker, MBChB,FFARCS,MRCP,FRCPCH         
Sponsors and Collaborators
Lumena Pharmaceuticals, Inc.
Investigators
Study Director: Alejandro Dorenbaum, MD Lumena Pharmaceuticals, Inc.
  More Information

Additional Information:
No publications provided

Responsible Party: Lumena Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier: NCT01903460     History of Changes
Other Study ID Numbers: LUM001-302, 2012-005346-38
Study First Received: July 16, 2013
Last Updated: September 16, 2014
Health Authority: United Kingdom: Medicines and Healthcare Products Regulatory Agency

Additional relevant MeSH terms:
Alagille Syndrome
Cholestasis
Liver Diseases
Syndrome
Abnormalities, Multiple
Bile Duct Diseases
Biliary Tract Diseases
Cardiovascular Abnormalities
Cardiovascular Diseases
Cholestasis, Intrahepatic
Congenital Abnormalities
Digestive System Diseases
Disease
Genetic Diseases, Inborn
Heart Defects, Congenital
Pathologic Processes

ClinicalTrials.gov processed this record on November 19, 2014